Company: TVRD
Filing Date: 2025-02-14
Form Type: S-4/A
Source: 0001104659-25-013053
Chunk: 573

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: S-4/A
Chunk 573
---
 | ​ | ​ | ​    | ​ | 10,223 | ​ | ​ | ​ | 1,358%   | ​ |
| License and milestone fees | ​ | ​ | ​                           | ​ |    910 | ​ | ​ | ​ | (94)%    | ​ | ​ | ​    | ​ | 15,000 | ​ | ​ | ​ | (29)%    | ​ |
| Royalty revenue            | ​ | ​ | ​                           | ​ |    415 | ​ | ​ | ​ | 476%     | ​ | ​ | ​    | ​ |     72 | ​ | ​ | ​ | N/A      | ​ |
| Clinical compound revenue  | ​ | ​ | ​                           | ​ |    165 | ​ | ​ | ​ | N/A      | ​ | ​ | ​    | ​ |      — | ​ | ​ | ​ | (100)%   | ​ |
| Other revenue              | ​ | ​ | ​                           | ​ |    699 | ​ | ​ | ​ | N/A      | ​ | ​ | ​    | ​ |      — | ​ | ​ | ​ | N/A      | ​ |
| Total revenue              | ​ | ​ | ​                           | $ | 20,968 | ​ | ​ | ​ | (50)%    | ​ | ​ | ​    | $ | 41,867 | ​ | ​ | ​ | 82%      | ​ |

Collaborative Revenue Cara recognized collaborative revenue of $12.9 million and $16.6 million for the years ended December 31, 2023 and 2022, respectively. Collaborative revenue was related to Cara’s share of the profit from CSL Vifor’s sales of KORSUVA injection to third parties in the United States, which commercially launched in April 2022, as well as $0.5 million earned in conjunction with the regulatory approval of KORSUVA injection in Japan for a milestone payment Cara earned in September 2023 from Maruishi that was allocated to the R&D services performance obligation under the Maruishi Agreement (see Notes 13 and 14 of Cara’s Notes to Consolidated Financial Statements as of December 31, 2023, Collaboration and Licensing Agreements and Revenue Recognition , respectively, included elsewhere in this proxy statement/ prospectus). Commercial Supply Revenue Cara recognized commercial supply revenue of $5.8 million and $10.2 million for the years ended December